Key result
Bioprostheses were associated with a higher actuarial risk of prosthetic valve endocarditis than mechanical valves but a lower risk of death.
Why the study?
Does the type of prosthetic valve (bioprosthetic vs mechanical) affect the risk of prosthetic valve endocarditis and subsequent mortality?
Cohort (n=1,810)
Does the type of prosthetic valve (bioprosthetic vs mechanical) affect the risk of prosthetic valve endocarditis and subsequent mortality?
Bioprosthetic valves are associated with a higher risk of prosthetic valve endocarditis but a lower risk of death compared to mechanical valves, with medical therapy showing higher success rates in bioprostheses.
Answers are grounded in this paper and cite their sources.
May inform valve selection discussions; leaves open whether randomized trials will confirm these associations.
Prosthetic valve endocarditis (PVE) was encountered in 42 out of 1810 patients (2.3%) who underwent valve replacement between 1971 and 1981. At an average follow-up time of 5.0 years (yr) the actuarial risk of PVE was 0.46 %/yr. The risk was lowest after aortic valve replacement (AVR): 0.37 %/yr, higher after mitral (MVR): 0.45%/ yr and highest after double valve replacement (AVR + MVR): 1.0%/yr. Bioprostheses (605 patients) were employed in large numbers after 1977; they had a higher actuarial risk of PVE than mechanical valves (1205 patients): 0.65 %/yr for bioprostheses versus 0.42 %/yr for mechanical valves. The risk of death was on the contrary, lower in the bioprostheses group: 0.12%/yr versus 0.19%/yr for mechanical valves. Medical treatment was attempted in 14 patients with 5 deaths (36%). The risk of death (surgery and medical treatment combined) was lower in AVR (27%) and higher in MVR (50%) and AVR + MVR (50%). Surgery carried the highest risk in emergency operations for prosthetic dysfunction (4/7 died); elective operations during or after medical treatment had no early mortality (7 patients). Medical therapy had a much higher success rate for bioprostheses (8/11 patients surviving, 73%) than for mechanical prostheses (9/31 patients, 29%).
No takes yet. Share an insight, caveat, or question.
M Turina (1982) conducted a cohort in Prosthetic valve endocarditis (n=1,810). Bioprostheses vs. Mechanical valves was evaluated on Actuarial risk of prosthetic valve endocarditis. Bioprostheses were associated with a higher actuarial risk of prosthetic valve endocarditis than mechanical valves but a lower risk of death.
Synapse has enriched 10 related papers. Consider them for comparative context: